Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. (Record no. 30820178)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02246 a2200589 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518094209.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202101s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1471-2407 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1186/s12885-020-06747-y |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Decker, Thomas |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20210104 |
| 245 00 - TITLE STATEMENT | |
| Title | Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | BMC cancer |
| Date of publication, distribution, etc. | Apr 2020 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 286 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Androstadienes |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Bevacizumab |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Breast Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Capecitabine |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cross-Over Studies |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Estrogen Receptor alpha |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Everolimus |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Patient Preference |
| General subdivision | statistics & numerical data |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Prognosis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Quality of Life |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptor, ErbB-2 |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptors, Progesterone |
| General subdivision | metabolism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Survival Rate |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Söling, Ulrike |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hahn, Antje |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Maintz, Christoph |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kurbacher, Christian Martin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vehling-Kaiser, Ursula |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sent, Dagmar |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Klare, Peter |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hagen, Volker |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Chiabudini, Marco |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Falkenstein, Julia |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Indorf, Martin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Runkel, Eva |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Potthoff, Karin |
| 773 0# - HOST ITEM ENTRY | |
| Title | BMC cancer |
| Related parts | vol. 20 |
| -- | no. 1 |
| -- | p. 286 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1186/s12885-020-06747-y">https://doi.org/10.1186/s12885-020-06747-y</a> |
| Public note | Available from publisher's website |
No items available.